AKARI THERAPEUTICS PLC-ADR (AKTX)

Company Profile

Akari Therapeutics PLC is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2014-01-31. Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The firm's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The firm has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the United States Food and Drug Administration (FDA) for nomacopan for the treatment of pediatric HSCT-TMA. Additionally, the Company has a pre-clinical program developing long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

Company Info

AKARI THERAPEUTICS PLC-ADR

22 Boston Wharf Road, Fl 7

Boston MASSACHUSETTS W1G 9RT

P: 16463500702

CEO: Clive Richardson

Employees: 15

Website: https://www.akaritx.com/